全文获取类型
收费全文 | 167466篇 |
免费 | 12408篇 |
国内免费 | 5295篇 |
专业分类
耳鼻咽喉 | 1056篇 |
儿科学 | 3982篇 |
妇产科学 | 1840篇 |
基础医学 | 12689篇 |
口腔科学 | 2101篇 |
临床医学 | 20658篇 |
内科学 | 23554篇 |
皮肤病学 | 1309篇 |
神经病学 | 12015篇 |
特种医学 | 7120篇 |
外国民族医学 | 7篇 |
外科学 | 26299篇 |
综合类 | 30088篇 |
现状与发展 | 6篇 |
一般理论 | 10篇 |
预防医学 | 15852篇 |
眼科学 | 4260篇 |
药学 | 14291篇 |
101篇 | |
中国医学 | 5662篇 |
肿瘤学 | 2269篇 |
出版年
2024年 | 452篇 |
2023年 | 2634篇 |
2022年 | 4857篇 |
2021年 | 6841篇 |
2020年 | 6229篇 |
2019年 | 7570篇 |
2018年 | 7281篇 |
2017年 | 6301篇 |
2016年 | 5552篇 |
2015年 | 5384篇 |
2014年 | 10852篇 |
2013年 | 11780篇 |
2012年 | 9689篇 |
2011年 | 10616篇 |
2010年 | 8637篇 |
2009年 | 7886篇 |
2008年 | 7819篇 |
2007年 | 7525篇 |
2006年 | 6979篇 |
2005年 | 5696篇 |
2004年 | 4700篇 |
2003年 | 4061篇 |
2002年 | 3325篇 |
2001年 | 3002篇 |
2000年 | 2450篇 |
1999年 | 2098篇 |
1998年 | 1758篇 |
1997年 | 1662篇 |
1996年 | 1348篇 |
1995年 | 1270篇 |
1994年 | 1060篇 |
1993年 | 830篇 |
1992年 | 765篇 |
1991年 | 636篇 |
1990年 | 587篇 |
1989年 | 523篇 |
1988年 | 471篇 |
1985年 | 1303篇 |
1984年 | 1783篇 |
1983年 | 1360篇 |
1982年 | 1417篇 |
1981年 | 1373篇 |
1980年 | 1196篇 |
1979年 | 1037篇 |
1978年 | 819篇 |
1977年 | 566篇 |
1976年 | 720篇 |
1975年 | 606篇 |
1974年 | 506篇 |
1973年 | 467篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
4.
《Urological Science》2015,26(2):144-146
Hydronephrosis with an undetermined pathology is a common condition detected in imaging studies. In urological clinical practice, it is a persistent dilemma to predict whether this condition will progress to result in the deterioration of renal function. Perfusion pressure flow study of the upper urinary tract, known as the Whitaker test, provides an alternative diagnostic tool for solving this condition. Perfusion pressure flow study has been criticized for its invasiveness, nonphysiological approach, and inconsistency in predicting outcomes. However, it continues to be used to evaluate difficult or equivocal cases and to provide an objective assessment of the upper urinary tract. 相似文献
5.
6.
目的:比较经鼻导管高流量吸氧(HFNC)与经鼻气道正压通气(nCPAP)在重症毛细支气管炎呼吸支持中的应用价值,为临床治疗方案的选择提供参考。方法:选取2016年12月至2018年12月我院儿科收治的重症毛细支气管炎患儿90例,采用随机数字表法分为观察组和对照组各45例。两组患儿入院后均给予常规综合治疗以保证呼吸道通畅,在此基础上观察组采用HFNC治疗,对照组采用nCPAP治疗,比较两组患儿治疗前和治疗24 h后呼吸频率、经皮血氧饱和度(TcSO2)、呼吸窘迫评分体系(CSS)评分、动脉血氧分压(PaO2)等呼吸相关指标及治疗前后临床症状体征改善情况。结果:两组患儿治疗24 h后呼吸频率、CSS评分均降低,且观察组降低程度更大,TcSO2、PaO2于治疗24 h后升高,观察组升高幅度较对照组明显;治疗后两组患儿咳嗽及肺部湿啰音、肺部炎症情况均改善,观察组症状体征消失时间早于对照组,差异均有统计学意义(P<0.05)。结论:重症毛细支气管炎患儿采用HFNC治疗可明显改善通气功能和临床症状,治疗效果优于nCPAP治疗,可扩大样本量进一步观察。 相似文献
7.
Factors predicting the development of pressure ulcers in an at‐risk population who receive standardized preventive care: secondary analyses of a multicentre randomised controlled trial 下载免费PDF全文
8.
《Gaceta sanitaria / S.E.S.P.A.S》2015,29(5):390-392
Chronic obstructive pulmonary disease (COPD) is a significant health problem in developed countries. We aimed to estimate the prevalence of COPD in a single Spanish healthcare area. We also aimed to assess if there are any differences in prevalence and spirometry use among primary care services by utilizing already registered information. We designed a cross-sectional study to determine the prevalence of COPD and the performance of spirometries in each primary care service. A total of 8,444 patients were diagnosed with COPD, with a prevalence of 2.6% for individuals older than 39 years. The prevalence increased with age and was much higher in men. Significant heterogeneity was found in the prevalence of COPD and spirometry use among primary care services. COPD was underdiagnosed and there was wide variability in spirometry use in our area. Greater efforts are needed to diagnose COPD in order to improve its clinical outcomes and to refine registries so that they can be used as reliable sources of information 相似文献
9.
《Ophthalmology》2020,127(11):1498-1506
10.